Clinical Trials · NCT00108004

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Name: Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Pramlintide

Phase: Phase 3
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 400
Start date: Apr 2003
Locations: 48 sites, United States
Primary endpoint: To investigate the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitus

View Pramlintide compound reference